GLP-1 Medications and Their Impact on Uterine Fibroids
- GLP-1 receptor agonists (glucagon-like peptide-1 agonists) are associated with a reduced risk of developing uterine fibroids.
- These medications may offer greater protective benefits compared to metformin and insulin.
Type 2 diabetes and obesity contribute to insulin resistance, which is linked to an increased risk of uterine fibroids. Since 2020, prescriptions for GLP-1 receptor agonists have surged, partly due to their weight-loss effects. Studies have demonstrated numerous benefits of GLP-1 receptor agonists, and the first study evaluating their impact on uterine fibroids (e.g., Wegovy, Ozempic) has been presented. Future research plans include investigating other antidiabetic drugs and combined outcomes for women with heavy menstrual bleeding, as well as exploring the effects of GLP-1 receptor agonists on women already diagnosed with fibroids.
A year-long use of GLP-1 receptor agonists showed no significant impact on the number of oocytes retrieved during controlled ovarian stimulation, according to data from 73 patients in a multicenter study. These findings indicate that most women using GLP-1 receptor agonists experience no substantial effect on oocyte and embryo yield.
It is important to note that overweight infertility patients have lower conception rates and higher risks of pregnancy complications. Thus, weight normalization before embryo transfer and pregnancy is a critical factor influencing implantation success and live birth outcomes. While GLP-1 receptor agonist use has sharply increased due to its efficacy for weight loss and diabetes treatment, its safety during pregnancy remains unclear. Current guidelines recommend discontinuing the medication 6-8 weeks prior to conception.
Economic Analysis of PGT-A (Preimplantation Genetic Testing for Aneuploidy)
An economic analysis of PGT-A in IVF treatment cycles for women aged 38-40 highlighted its value in reducing overall treatment costs by lowering miscarriage rates, minimizing failed embryo transfers, and reducing the incidence of multiple pregnancies.
Clinical Outcomes of Mosaic Embryo Transfer
Data were presented comparing the clinical outcomes of transferring mosaic embryos based on the type and degree of mosaicism versus transferring a euploid embryo.
- Embryos were classified as normal, mosaic, or abnormal based on chromosomal findings in 80%, 20-80%, and less than 20% of nuclei, respectively.
- Mosaic embryos were further categorized into four groups based on mosaicism levels (low: <50%; high: >50%) and types of chromosomal abnormalities (segmental or full chromosomal abnormalities).
- Clinical pregnancy was defined as the presence of a gestational sac observed on ultrasound at 6-7 weeks of pregnancy.
The results suggest that mosaic embryos, excluding those with high-level mosaicism, may be a viable transfer option when euploid embryos are unavailable.
This study encourages clinicians to consider mosaic embryos, except for high-level mosaicism, as a transfer option for patients struggling to obtain euploid embryos.
Advancements in Smart PGT-A Plus
Smart PGT-A Plus was presented as a promising option for:
- Couples with previous failed IVF cycles.
- Recurrent pregnancy loss during gestation.
- Previous pregnancies diagnosed with triploidy or recurrent triploid conditions.
- Patients with high-quality embryos but indicators of abnormal fertilization (one or three pronuclei).
- Miscarriage following the transfer of a euploid embryo despite prior PGT-A testing.
These findings emphasize the potential utility of advanced genetic testing methods like Smart PGT-A Plus in addressing complex reproductive challenges.
